MRK — Merck & Co., Inc.
$145.27-1.34%
Last close: · regular session
Last 60 sessions
MRK closed at $145.27 (-1.34%) on Oct 23, 2026. Float: 2.4B shares. Latest SEC filing: 10-Q on Aug 7, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MRK in the TickerWise workspace.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NYSE
- Employees: 73,000
- Website: https://www.merck.com
Latest SEC filings for MRK
Latest MRK news
- Merck (MRK) Stock Dips While Market Gains: Key Facts Read article
- Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock Read article
- Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? Read article
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make Read article
- Merck (MRK) Dips More Than Broader Market: What You Should Know Read article
- Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors Read article
- Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026 Read article
- Jefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concerns Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.